BRAF and melanoma: Forthun et al. conducted a study [16] of bevacizumab in the treatment of metastatic malignant melanoma and showed that  ≤1% BRAF/NRAS-positive ctDNA before and during treatment reflected a positive response to therapy, through an increase in the durations of PFS and OS.